Table 1 Allele frequency distribution of the COMT V158M polymorphism in the Australian and Polish HNPCC MMR mutation positive patients
Group | Population | Val/Val (%) | Val/Met (%) | Met/Met (%) | n | Pearson's Chi-squared |
|---|---|---|---|---|---|---|
subject group | Australia | 53 (26.9) | 108 (54.8) | 36 (18.3) | 197 | p = 0.02 |
| Â | Poland | 33 (24.6) | 59 (44.0) | 42 (31.3) | 134 | Â |
hMLH1 mutation carriers | Australia | 31 (28.7) | 59 (54.6) | 18 (16.7) | 108 | p = 0.03 |
| Â | Poland | 17 (23.0) | 32 (43.2) | 25 (33.8) | 74 | Â |
hMSH2 mutation carriers | Australia | 22 (24.7) | 49 (55.1) | 18 (20.2) | 89 | p = 0.41 |
| Â | Poland | 16 (26.7) | 27 (45.0) | 17 (28.3) | 60 | Â |
mutation type: truncation/deletion | Australia | 50 (28.2) | 95 (53.7) | 32 (18.1) | 177 | p = 0.05 |
| Â | Poland | 26 (24.1) | 49 (45.4) | 33 (30.6) | 108 | Â |
mutation type: missense | Australia | 3 (15.0) | 13 (65.0) | 4 (20.0) | 20 | p = 0.20 |
| Â | Poland | 7 (26.9) | 10 (38.5) | 9 (30.6) | 26 | Â |
affected with CRC | Australia | 24 (25.5) | 51 (54.3) | 19 (20.2) | 94 | p = 0.88 |
| Â | Poland | 14 (25.5) | 28 (50.9) | 13 (23.6) | 55 | Â |
unaffected with CRC | Australia | 28 (28.3) | 53 (53.5) | 18 (18.2) | 99 | p = 0.02 |
| Â | Poland | 19 (24.1) | 31 (39.2) | 29 (36.7) | 79 | Â |
unaffected with CRC (>45 years) | Australia | 10 (23.3) | 24 (55.8) | 9 (20.9) | 43 | p = 0.84 |
| Â | Poland | 5 (22.7) | 11 (50) | 6 (27.2) | 22 | Â |
endometrial/ovarian cancer | Australia | 6 (26.1) | 14 (60.9) | 3 (13.0) | 23 | p = 0.12 |
| Â | Poland | 5 (35.7) | 4 (28.6) | 5 (35.7) | 14 | Â |
affected with CRC and unaffected | Australia | 22 (22.7) | 57 (58.8) | 18 (18.6) | 97 | p = 0.09 |
with endometrial/ovarian cancer | Poland* | 28 (23.3) | 55 (45.8) | 37 (30.8) | 120 | Â |